Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | Director · Co-CEO | August 10, 2026 | August 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date August 10, 2026 · Filed August 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | IndirectBy Limited Liability Companies | 6,381,734 |
Reported balance
After 2026-08-10 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-08-10 · Grant · Acquired 6,381,734 · Balance 6,381,734 F1: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition. |
| Class A Common StockSEC Table I · non-derivative | Direct | 1,388,521 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,388,521 |
| Class A Common StockSEC Table I · non-derivative | IndirectBy Family Trusts | 24,753,252 |
Reported balance
Holding disclosure · report date 2026-08-10 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 24,753,252 |
Filing footnotes · ownership attribution and instrument terms
F1: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 12, 2026 20:46 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantClass A Common Stock | 6,381,734 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-056297 · wk-form4_1786567594.xml · nonDerivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Limited Liability Companies Disclosed balance after: 6,381,734 F1 · kind: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition. F1 · price: On August 10, 2026, pursuant to a Membership Interest Purchase Agreement, dated as of April 21, 2026 (as amended from time to time, the Purchase Agreement), by and among the Issuer, Kashiv BioSciences, LLC (Kashiv), KB Seller Representative, LLC and the equity holders of Kashiv named therein (the Sellers), a subsidiary of the Issuer purchased (the Acquisition) from the Sellers 100% of the issued and outstanding membership interests of Kashiv for an aggregate consideration of $375,000,000 in cash, subject to certain purchase price adjustments, and 28,942,098 shares of Issuer Class A common stock (Class A Common Stock). Pursuant to the terms of the Purchase Agreement, limited liability companies managed by the Reporting Person received 6,381,734 shares of Class A Common Stock in the Acquisition. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:52 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 92,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015285 · wk-form4_1772747542.xml · derivative · entry 10 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,185 Underlying: Class A Common Stock · 92,593 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: On March 4, 2024, the reporting person was granted 370,370 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F7 · derivative.expiration_date: On March 4, 2024, the reporting person was granted 370,370 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:52 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 28,983 | $13.30 | $385,473.90 |
DisclosureSEC source: 0001628280-26-015285 · wk-form4_1772747542.xml · nonDerivative · entry 6 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,388,521 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 04, 2026 Filed Mar 5, 2026 21:52 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 92,593 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015285 · wk-form4_1772747542.xml · nonDerivative · entry 5 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,417,504 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:52 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 733,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015285 · wk-form4_1772747542.xml · derivative · entry 9 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 733,944 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. F4 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:52 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 59,931 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-015285 · wk-form4_1772747542.xml · derivative · entry 8 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,795 Underlying: Class A Common Stock · 59,931 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F6 · derivative.exercise_date: On March 3, 2025, the Reporting Person was granted 239,726 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F6 · derivative.expiration_date: On March 3, 2025, the Reporting Person was granted 239,726 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:52 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 315,885 | $13.31 | $4,204,429.35 |
DisclosureSEC source: 0001628280-26-015285 · wk-form4_1772747542.xml · nonDerivative · entry 4 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,324,911 F5 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:52 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 733,944 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015285 · wk-form4_1772747542.xml · nonDerivative · entry 3 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,640,796 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:52 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 17,112 | $13.31 | $227,760.72 |
DisclosureSEC source: 0001628280-26-015285 · wk-form4_1772747542.xml · nonDerivative · entry 2 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 906,852 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 03, 2026 Filed Mar 5, 2026 21:52 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 59,931 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-015285 · wk-form4_1772747542.xml · nonDerivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 923,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:29 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 354,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013900 · wk-form4_1772573379.xml · derivative · entry 2 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 354,031 Underlying: Class A Common Stock · 354,031 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period. F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 354,031 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 21:29 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 190,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013900 · wk-form4_1772573379.xml · derivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,632 Underlying: Class A Common Stock · 190,632 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 2, 2027. Read SEC document |
| March 02, 2026 Filed Mar 27, 2026 20:20 UTC Amendment | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 544,663 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-021746 · wk-form4a_1774642844.xml · derivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 544,663 Underlying: Class A Common Stock · 544,663 shares Expires not disclosed F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period. F2 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 544,663 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2029, the last day of the performance period. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 92,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010688 · wk-form4_1741221088.xml · derivative · entry 9 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277,778 Underlying: Class A Common Stock · 92,592 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F9 · derivative.exercise_date: On March 4, 2024, the Reporting Person was granted 370,370 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. F9 · derivative.expiration_date: On March 4, 2024, the Reporting Person was granted 370,370 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 46,528 | $8.84 | $411,307.52 |
DisclosureSEC source: 0001628280-25-010688 · wk-form4_1741221088.xml · nonDerivative · entry 4 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 864,033 F5 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 00:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 92,592 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010688 · wk-form4_1741221088.xml · nonDerivative · entry 3 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 910,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issues was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5 F4 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 239,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010688 · wk-form4_1741221088.xml · derivative · entry 8 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,726 Underlying: Class A Common Stock · 239,726 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F8 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2026. F8 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 3, 2026. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 890,410 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010688 · wk-form4_1741221088.xml · derivative · entry 7 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 890,410 Underlying: Class A Common Stock · 890,410 shares Expires not disclosed F6 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F7 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 445,205 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units will be deemed earned and vested when settled into shares of Class A Common Stock shortly after February 28, 2028, the last day of the performance period. F7 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 445,205 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units will be deemed earned and vested when settled into shares of Class A Common Stock shortly after February 28, 2028, the last day of the performance period. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionPerformance-Based Restricted Stock Units · Derivative | 579,710 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-010688 · wk-form4_1741221088.xml · derivative · entry 6 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 579,710 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one -for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 2. F1 · derivative.exercise_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one -for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 2. F1 · derivative.expiration_date: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one -for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 2. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 274,307 | $8.76 | $2,402,929.32 |
DisclosureSEC source: 0001628280-25-010688 · wk-form4_1741221088.xml · nonDerivative · entry 2 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 817,969 F2 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 00:31 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 579,710 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-010688 · wk-form4_1741221088.xml · nonDerivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,092,276 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2022, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 100% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2025 and settled into shares of Class A Common Stock on a one -for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 2. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 1,333,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-009481 · wk-form4_1709764798.xml · derivative · entry 2 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,333,334 Underlying: Class A Common Stock · 1,333,334 shares Expires not disclosed F3 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: Represents a performance-based restricted stock unit grant 666,667 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period. F4 · derivative.expiration_date: Represents a performance-based restricted stock unit grant 666,667 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2027, the last day of the performance period. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 22:40 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 370,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-009481 · wk-form4_1709764798.xml · derivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 370,370 Underlying: Class A Common Stock · 370,370 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on March 4, 2025. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on March 4, 2025. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 23:20 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass B Common Stock and Common Units · Derivative | 24,753,252 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054738 · doc4.xml · derivative · entry 3 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trusts Disclosed balance after: 0 Underlying: Class A Common Stock · 24,753,252 shares Expires not disclosed F3 · security: The Issuer of the Common Units is Amneal Pharmaceuticals, LLC. F2 · derivative.exercise_price: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F2 · price: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F2 · derivative.exercise_date: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. F2 · derivative.expiration_date: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. Read SEC document |
| November 07, 2023 Filed Nov 8, 2023 23:20 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass A Common Stock | 24,753,252 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-054738 · doc4.xml · nonDerivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Family Trusts Disclosed balance after: 24,753,252 F1 · security: On November 7, 2023, Amneal Pharmaceuticals, Inc. (formerly known as Amneal NewCo Inc.) (the "Issuer") became the successor of Amneal Intermediate Inc. (formerly known as Amneal Pharmaceuticals, Inc.) ("Old PubCo") pursuant to merger transactions, in which a subsidiary of the Issuer merged with and into Old PubCo with Old PubCo surviving and, immediately following such merger, a subsidiary of the Issuer merged with and into Amneal Pharmaceuticals, LLC ("AP"), an indirect subsidiary of the Issuer, with AP surviving. The transactions resulted in the Issuer becoming a parent holding company of Old PubCo and AP. As a result of the transactions, there is a single class of stock of the Issuer outstanding, and the proportionate economic and voting rights of security holders in the Issuer are identical to the direct and indirect economic and voting rights held in Old PubCo and AP prior to the transactions. F2 · price: Prior to the transactions, pursuant to the terms of the limited liability company agreement for AP, limited liability common units (each unit representing a fractional part of the Reporting Person's interest in the profits, losses and distributions of AP) ("AP Units") and an equal number of shares of Class B Common Stock of Old PubCo, together were redeemable at any time for shares of Class A Common Stock of Old PubCo on a one-for-one basis at the discretion of the holder, subject to exchange rate adjustments for stock splits, stock dividends, and reclassifications. In connection with the transactions, the AP Units held by the Reporting Person were exchanged on a one-for-one basis for shares of Class A Common Stock of the Issuer, and all of the shares of Class B Common Stock of the Issuer held by the Reporting Person were surrendered to the Issuer for no consideration. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 23:00 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 733,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-016932 · doc4.xml · derivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 733,944 Underlying: Class A Common Stock · 733,944 shares Expires not disclosed F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · shares: Represents a performance-based restricted stock unit grant of 366,972 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F2 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 366,972 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F2 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 366,972 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F2 · derivative.underlying_shares: Represents a performance-based restricted stock unit grant of 366,972 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. F2 · balance_after: Represents a performance-based restricted stock unit grant of 366,972 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing price per share targets at the end of the three-year performance period. The number of shares that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2026, the last day of the performance period. Read SEC document |
| March 03, 2022 Filed Mar 4, 2022 02:19 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 1,159,420 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-016051 · doc4.xml · derivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,159,420 Underlying: Class A Common Stock · 1,159,420 shares Expires not disclosed F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · shares: Represents a performance-based restricted stock unit grant of 579,710 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F2 · derivative.exercise_date: Represents a performance-based restricted stock unit grant of 579,710 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F2 · derivative.expiration_date: Represents a performance-based restricted stock unit grant of 579,710 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F2 · derivative.underlying_shares: Represents a performance-based restricted stock unit grant of 579,710 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. F2 · balance_after: Represents a performance-based restricted stock unit grant of 579,710 target shares. The performance-based restricted stock units are scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. The number of performance-based restricted stock units reported represents the maximum number of shares issuable under the award. The number that would be received upon vesting, if any, may vary from 0% to 200% of the target number. The number of performance-based restricted stock units reported in the table above represents the maximum number of shares issuable under the award. Any earned performance-based restricted stock units vest in full on February 28, 2025, the last day of the performance period. Read SEC document |
| December 16, 2021 Filed Dec 17, 2021 21:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 50,000 | $4.25 | $212,500.00 |
DisclosureSEC source: 0001209191-21-070258 · doc4.xml · nonDerivative · entry 2 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512,566 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.30. The reporting person undertakes to provide the Company, any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 15, 2021 Filed Dec 17, 2021 21:15 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 100,000 | $4.13 | $413,000.00 |
DisclosureSEC source: 0001209191-21-070258 · doc4.xml · nonDerivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 462,566 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.06 to $4.18. The reporting person undertakes to provide Amneal Pharmaceuticals, Inc. (the "Company"), any security holder of the Company, or of the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 22:07 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 926,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-017006 · doc4.xml · derivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 926,640 Underlying: Class A Common Stock · 926,640 shares Expires not disclosed F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · shares: Represents the maximum number of shares issuable under the performance-based restricted stock units. F3 · derivative.exercise_date: 50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period. F3 · derivative.expiration_date: 50% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. Additional performance-based restricted stock units are earned at higher levels and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10 (75%), $12 (100%), $14 (125%), $16 (150%), $18 (175%) and $20 (200%), respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 29,2024, the last day of the performance period. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:09 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-012444 · doc4.xml · derivative · entry 2 Patel Chintu · CIK 0001737428 · Director · Co-CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · derivative.exercise_date: On May 6, 2019, the reporting person was granted 6,459 restricted stock units vesting on May 7, 2020. F2 · derivative.expiration_date: On May 6, 2019, the reporting person was granted 6,459 restricted stock units vesting on May 7, 2020. Read SEC document |
| May 07, 2020 Filed May 8, 2020 23:09 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,459 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012444 · doc4.xml · nonDerivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 362,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| March 10, 2020 Filed Mar 11, 2020 23:54 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 100,000 | $3.09 | $309,000.00 |
DisclosureSEC source: 0000899243-20-007990 · doc4.xml · nonDerivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 356,107 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.90 to $3.20, inclusive. Read SEC document |
| March 04, 2020 Filed Mar 11, 2020 01:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 58,765 | $3.97 | $233,297.05 |
DisclosureSEC source: 0000899243-20-007819 · doc4.xml · nonDerivative · entry 3 Patel Chintu · CIK 0001737428 · Director · Co-CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,107 F3 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.87 to $4.00, inclusive. Read SEC document |
| March 03, 2020 Filed Mar 11, 2020 01:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 156,539 | $3.88 | $607,371.32 |
DisclosureSEC source: 0000899243-20-007819 · doc4.xml · nonDerivative · entry 2 Patel Chintu · CIK 0001737428 · Director · Co-CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,342 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.75 to $4.00, inclusive. Read SEC document |
| March 02, 2020 Filed Mar 11, 2020 01:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | PurchaseClass A Common Stock | 34,696 | $3.87 | $134,273.52 |
DisclosureSEC source: 0000899243-20-007819 · doc4.xml · nonDerivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,803 F1 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $3.805 to $3.92, inclusive. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 01:18 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantPerformance-Based Restricted Stock Units · Derivative | 1,266,490 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-006635 · doc4.xml · derivative · entry 1 Patel Chintu · CIK 0001737428 · Director · Co-CEO and Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,266,490 Underlying: Class A Common Stock · 1,266,490 shares Expires not disclosed F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F2 · shares: Represents the maximum number of shares issuable under the performance-based restricted stock units. F3 · derivative.exercise_date: 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period. F3 · derivative.expiration_date: 25% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $8 or higher for 60 consecutive calendar days during the three-year performance period. An additional 12.5% of the performance-based restricted stock units are earned and eligible to vest upon the Issuer's Class A Common Stock achieving an average closing price per share of $10, $12, $14, $16, $18 and $20, respectively, for 60 consecutive calendar days during the three-year performance period. For average 60-day closing stock prices between $12 and $20 per share, the number of performance-based restricted stock units that become earned will be determined using straight line interpolation. Any earned performance-based restricted stock units vest in full on February 28, 2023, the last day of the performance period. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:49 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000072 · wf-form4_155735213416964.xml · derivative · entry 4 Patel Chintu · CIK 0001737428 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. F4 · derivative.expiration_date: On May 7, 2018, the reporting person was granted 6,107 restricted stock units vesting on May 8, 2019. Read SEC document |
| May 08, 2019 Filed May 8, 2019 21:49 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 6,107 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723128-19-000072 · wf-form4_155735213416964.xml · nonDerivative · entry 1 Patel Chintu · CIK 0001737428 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:49 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,459 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000072 · wf-form4_155735213416964.xml · derivative · entry 3 Patel Chintu · CIK 0001737428 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,459 Underlying: Class A Common Stock · 6,459 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. F3 · derivative.expiration_date: Restricted stock units vest on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Restricted stock units have no expiration date. Read SEC document |
| May 06, 2019 Filed May 8, 2019 21:49 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 28,044 | $0.00 Strike: $14.05 | $0.00 |
DisclosureSEC source: 0001723128-19-000072 · wf-form4_155735213416964.xml · derivative · entry 2 Patel Chintu · CIK 0001737428 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,044 Underlying: Class A Common Stock · 28,044 shares Expires 2029-05-06 F2 · derivative.exercise_date: The option vests on the later of (i) the day immediately preceeding the issuer's first annual meeting of stockholders following the date of grant and (ii) the day immediately following the first anniversary of the date of grant. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 21:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherCommon Units · Derivative | 24,753,252 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019663 · doc4.xml · derivative · entry 2 Patel Chintu · CIK 0001737428 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trusts Disclosed balance after: 24,753,252 Underlying: Common Units · 24,753,252 shares Expires not disclosed F2 · derivative.exercise_price: The Common Units may be redeemed at any time for shares of the Issuer's Class A Common Stock on a 1-to-1 basis. F1 · kind: Represents a pro rata in-kind distribution of Class B Common Stock and Common Units from APHC Holdings, LLC to its members for no consideration. F2 · derivative.exercise_date: The Common Units may be redeemed at any time for shares of the Issuer's Class A Common Stock on a 1-to-1 basis. F2 · derivative.expiration_date: The Common Units may be redeemed at any time for shares of the Issuer's Class A Common Stock on a 1-to-1 basis. Read SEC document |
| July 05, 2018 Filed Jul 9, 2018 21:13 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | OtherClass B Common Stock | 24,753,252 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-019663 · doc4.xml · nonDerivative · entry 1 Patel Chintu · CIK 0001737428 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Family Trusts Disclosed balance after: 24,753,252 F1 · kind: Represents a pro rata in-kind distribution of Class B Common Stock and Common Units from APHC Holdings, LLC to its members for no consideration. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:34 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 6,107 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-012152 · doc4.xml · derivative · entry 2 Patel Chintu · CIK 0001737428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,107 Underlying: Class A Common Stock · 6,107 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on May 07, 2019 and have no expiration date. Read SEC document |
| May 07, 2018 Filed May 9, 2018 22:34 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 24,977 | $0.00 Strike: $15.01 | $0.00 |
DisclosureSEC source: 0000899243-18-012152 · doc4.xml · derivative · entry 1 Patel Chintu · CIK 0001737428 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,977 Underlying: Class A Common Stock · 24,977 shares Expires 2028-05-07 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on May 07, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.